Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

H. Avet-Loiseau, R. Fonseca, D. Siegel, MA. Dimopoulos, I. Špička, T. Masszi, R. Hájek, L. Rosiñol, V. Goranova-Marinova, G. Mihaylov, V. Maisnar, MV. Mateos, M. Wang, R. Niesvizky, A. Oriol, A. Jakubowiak, J. Minarik, A. Palumbo, W. Bensinger,...

. 2016 ; 128 (9) : 1174-80. [pub] 20160720

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031568

The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly improved with carfilzomib, lenalidomide, and dexamethasone (KRd), compared with lenalidomide and dexamethasone (Rd) in relapsed MM. This preplanned subgroup analysis of ASPIRE was conducted to evaluate KRd vs Rd by baseline cytogenetics according to fluorescence in situ hybridization. Of 417 patients with known cytogenetic risk status, 100 patients (24%) were categorized with high-risk cytogenetics (KRd, n = 48; Rd, n = 52) and 317 (76%) were categorized with standard-risk cytogenetics (KRd, n = 147; Rd, n = 170). For patients with high-risk cytogenetics, treatment with KRd resulted in a median PFS of 23.1 months, a 9-month improvement relative to treatment with Rd. For patients with standard-risk cytogenetics, treatment with KRd led to a 10-month improvement in median PFS vs Rd. The overall response rates for KRd vs Rd were 79.2% vs 59.6% (high-risk cytogenetics) and 91.2% vs 73.5% (standard-risk cytogenetics); approximately fivefold as many patients with high- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2% vs 5.8% and 38.1% vs 6.5%, respectively). KRd improved but did not abrogate the poor prognosis associated with high-risk cytogenetics. This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01080391.

Centre de Recherche en Cancérologie de Toulouse INSERM U1037 Toulouse France

Charles University Faculty Hospital and Faculty of Medicine Hradec Králové Czech Republic

Department of Hemato oncology University Hospital Olomouc Olomouc Czech Republic

Department of Internal Medicine University Hospital Praha Czech Republic

Fred Hutchinson Cancer Research Center Seattle WA

Hadassah Hebrew University Medical Center Jerusalem Israel

Hematology Clinic University Multiprofile Hospital for Active Treatment Sv Georgi and Medical University Plovdiv Bulgaria

Hospital Clínic de Barcelona Barcelona Spain

Institut Català d'Oncologia Institut Josep Carreras Hospital Germans Trias i Pujol Barcelona Spain

John Theurer Cancer Center at Hackensack University Hackensack NJ

L'Institut Universitaire du Cancer de Toulouse Oncopole Centre Hospitalier Universitaire Toulouse France

Mayo Clinic Scottsdale AZ

National and Kapodistrian University of Athens Athens Greece

Onyx Pharmaceuticals Inc South San Francisco CA

Princess Margaret Cancer Centre Toronto ON Canada

Queen Joanna University Hospital Sofia Bulgaria

St István and St Laszlo Hospital Budapest Hungary

The University of Texas MD Anderson Cancer Center Houston TX

University Hospital of Salamanca Instituto de Investigación Biomédica de Salamanca Salamanca Spain

University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

University of Chicago Medical Center Chicago IL

University of Nantes Nantes France

University of Torino Torino Italy

Weill Cornell Medical College New York Presbyterian Hospital New York NY

000      
00000naa a2200000 a 4500
001      
bmc17031568
003      
CZ-PrNML
005      
20171025123042.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2016-03-707596 $2 doi
035    __
$a (PubMed)27439911
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Avet-Loiseau, Hervé $u Centre de Recherche en Cancérologie de Toulouse INSERM U1037, Toulouse, France; L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France; $7 gn_A_00010337
245    10
$a Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma / $c H. Avet-Loiseau, R. Fonseca, D. Siegel, MA. Dimopoulos, I. Špička, T. Masszi, R. Hájek, L. Rosiñol, V. Goranova-Marinova, G. Mihaylov, V. Maisnar, MV. Mateos, M. Wang, R. Niesvizky, A. Oriol, A. Jakubowiak, J. Minarik, A. Palumbo, W. Bensinger, V. Kukreti, D. Ben-Yehuda, AK. Stewart, M. Obreja, P. Moreau,
520    9_
$a The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that progression-free survival (PFS) was significantly improved with carfilzomib, lenalidomide, and dexamethasone (KRd), compared with lenalidomide and dexamethasone (Rd) in relapsed MM. This preplanned subgroup analysis of ASPIRE was conducted to evaluate KRd vs Rd by baseline cytogenetics according to fluorescence in situ hybridization. Of 417 patients with known cytogenetic risk status, 100 patients (24%) were categorized with high-risk cytogenetics (KRd, n = 48; Rd, n = 52) and 317 (76%) were categorized with standard-risk cytogenetics (KRd, n = 147; Rd, n = 170). For patients with high-risk cytogenetics, treatment with KRd resulted in a median PFS of 23.1 months, a 9-month improvement relative to treatment with Rd. For patients with standard-risk cytogenetics, treatment with KRd led to a 10-month improvement in median PFS vs Rd. The overall response rates for KRd vs Rd were 79.2% vs 59.6% (high-risk cytogenetics) and 91.2% vs 73.5% (standard-risk cytogenetics); approximately fivefold as many patients with high- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2% vs 5.8% and 38.1% vs 6.5%, respectively). KRd improved but did not abrogate the poor prognosis associated with high-risk cytogenetics. This regimen had a favorable benefit-risk profile in patients with relapsed MM, irrespective of cytogenetic risk status, and should be considered a standard of care in these patients. This trial was registered at www.clinicaltrials.gov as #NCT01080391.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a oligopeptidy $x aplikace a dávkování $7 D009842
650    _2
$a recidiva $7 D012008
650    _2
$a rizikové faktory $7 D012307
650    _2
$a míra přežití $7 D015996
650    _2
$a thalidomid $x aplikace a dávkování $x analogy a deriváty $7 D013792
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Fonseca, Rafael $u Mayo Clinic, Scottsdale, AZ;
700    1_
$a Siegel, David $u John Theurer Cancer Center at Hackensack University, Hackensack, NJ;
700    1_
$a Dimopoulos, Meletios A $u National and Kapodistrian University of Athens, Athens, Greece;
700    1_
$a Špička, Ivan $u Department of Internal Medicine, University Hospital, Praha, Czech Republic;
700    1_
$a Masszi, Tamás $u St. István and St. Laszlo Hospital, Budapest, Hungary;
700    1_
$a Hájek, Roman $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
700    1_
$a Rosiñol, Laura $u Hospital Clínic de Barcelona, Barcelona, Spain;
700    1_
$a Goranova-Marinova, Vesselina $u Hematology Clinic University Multiprofile Hospital for Active Treatment "Sv. Georgi" and Medical University, Plovdiv, Bulgaria;
700    1_
$a Mihaylov, Georgi $u Queen Joanna University Hospital, Sofia, Bulgaria;
700    1_
$a Maisnar, Vladimír $u Charles University Faculty Hospital and Faculty of Medicine, Hradec Králové, Czech Republic;
700    1_
$a Mateos, Maria-Victoria $u University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain;
700    1_
$a Wang, Michael $u The University of Texas MD Anderson Cancer Center, Houston, TX;
700    1_
$a Niesvizky, Ruben $u Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY;
700    1_
$a Oriol, Albert $u Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;
700    1_
$a Jakubowiak, Andrzej $u University of Chicago Medical Center, Chicago, IL;
700    1_
$a Minarik, Jiri $u Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic;
700    1_
$a Palumbo, Antonio $u University of Torino, Torino, Italy;
700    1_
$a Bensinger, William $u Fred Hutchinson Cancer Research Center, Seattle, WA;
700    1_
$a Kukreti, Vishal $u Princess Margaret Cancer Centre, Toronto, ON, Canada;
700    1_
$a Ben-Yehuda, Dina $u Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
700    1_
$a Stewart, A Keith $u Mayo Clinic, Scottsdale, AZ;
700    1_
$a Obreja, Mihaela $u Onyx Pharmaceuticals Inc., South San Francisco, CA; and.
700    1_
$a Moreau, Philippe $u University of Nantes, Nantes, France.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 128, č. 9 (2016), s. 1174-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27439911 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123124 $b ABA008
999    __
$a ok $b bmc $g 1255161 $s 992595
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 128 $c 9 $d 1174-80 $e 20160720 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace